Investment Thesis
Rallybio is an early-stage pharmaceutical company with minimal revenue ($212K), severe operating losses (-$8.7M), and significant cash burn (-$8M), indicating no near-term path to profitability despite balance sheet strength. While management has improved losses by 84.5% YoY and maintains a fortress balance sheet with $41.3M cash against minimal debt, the company is essentially pre-revenue with extreme negative margins (-4119% operating margin), raising fundamental concerns about business viability absent transformative clinical or commercial events.
Strengths
- Fortress balance sheet with $41.3M cash, $4.2M liabilities, zero debt providing 4-5 year cash runway
- Exceptional liquidity position (12.92x current ratio) ensuring short-term solvency
- Revenue growth of 34.9% YoY shows early traction despite negligible base
Risks
- Essentially pre-revenue company with only $212K annual revenue and no gross profit data
- Severe negative cash flow (-$8.0M operating cash flow) at unsustainable burn rate
- Extreme operating losses (-$8.7M) and negative margins (-4119% operating margin) with no visible profitability path
- Typical pre-clinical/early-stage biotech with binary outcome risk (success/failure dependent on clinical trials and regulatory approval)
Key Metrics to Watch
- Revenue growth trajectory and commercial milestones
- Monthly cash burn rate and runway extension
- Clinical trial progress and pipeline advancement announcements
Financial Metrics
Revenue
212.0K
Net Income
-8.3M
EPS (Diluted)
$-1.46
Free Cash Flow
-8.0M
Total Assets
54.5M
Cash
41.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,119.3%
Net Margin
-3,904.7%
ROE
-16.5%
ROA
-15.2%
FCF Margin
-3,763.2%
Balance Sheet & Liquidity
Current Ratio
12.92x
Quick Ratio
12.92x
Debt/Equity
0.00x
Debt/Assets
7.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:09:41.971316 |
Data as of: 2026-03-31 |
Powered by Claude AI